Reports assess risk and benefit of list of medicines

ANVISA has announced the availability of the list of medicines that Drug Registration Holders (DRMs) must submit Periodic Benefit-Risk Assessment Reports (RPBRs) for by June 30, 2024. Read more here

ELS can help from the development to the registration of medicines in Brazil, Latin America and Europe.

Please do not hesitate to contact your local ELS consultant or via email

Contact us

We will contact you as soon as possible.